Kuwait Glp-1 Receptor Agonist Market Size & Outlook
Kuwait glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
Kuwait glp-1 receptor agonist market highlights
- The Kuwait glp-1 receptor agonist market generated a revenue of USD 56.1 million in 2023 and is expected to reach USD 265.4 million by 2030.
- The Kuwait market is expected to grow at a CAGR of 24.9% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 56.1 million |
| Market revenue in 2030 | USD 265.4 million |
| Growth rate | 24.9% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Saxenda, Victoza (liraglutide), Other Products |
Other key industry trends
- In terms of revenue, Kuwait accounted for 0.2% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, South Africa glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 371.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Kuwait glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 55.79% in 2023. Horizon Databook has segmented the Kuwait glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, saxenda, victoza (liraglutide), other products covering the revenue growth of each sub-segment from 2018 to 2030.
The GLP-1 receptor agonist market in Kuwait is expected to witness significant growth, driven by the high prevalence of diabetes and obesity. In 2021, Kuwait had around 803,000 adults with diabetes, with an age-adjusted prevalence of 24.9%. In addition, IGT affected around 582,000 people, and Impaired Fasting Glucose (IFG) was reported in 461,000 individuals. Diabetes-related mortality reached around 2,153 deaths.
The healthcare expenditure for diabetes was USD 1.5 billion. Type 1 diabetes cases included 0.4 per 1,000 children aged 0-14 years. The data highlights a growing diabetes burden, which is driving the demand for advanced treatment solutions.
Moreover, the high prevalence of diabetes in Kuwait and significant rates of IGT & IFG create a substantial opportunity for GLP-1 receptor agonists. These medications can help address the unmet need for effective diabetes management and glycemic control.
Reasons to subscribe to Kuwait glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Kuwait glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Kuwait glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into Kuwait glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Kuwait glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
Kuwait GLP-1 Receptor Agonist Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
